- Home
- RUM vs PHVS Comparison
RUM vs PHVS Comparison
Compare RUM & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUM | PHVS |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RUM | PHVS |
|---|---|---|
| Price | $5.88 | $26.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $10.00 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 2.0M | 130.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $171.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.11 | $11.51 |
| 52 Week High | $12.15 | $29.80 |
Technical Indicators
Market Signals| Indicator | RUM | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.94 | 50.53 |
| Support Level | $5.65 | $25.65 |
| Resistance Level | $5.83 | $28.79 |
| Average True Range (ATR) | 0.34 | 1.44 |
| MACD | 0.03 | -0.11 |
| Stochastic Oscillator | 49.56 | 46.06 |
Price Performance
Historical ComparisonAbout RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.